"
Vulvovaginal Candidiasis - Pipeline Review, H1 2016 " is the
latest addition to MarketResearchReports.Biz industry research
reports collection.
Global
Markets Directs, Vulvovaginal
Candidiasis - Pipeline Review, H1 2016,
provides an overview of the Vulvovaginal Candidiasis pipeline
landscape.
The
report provides comprehensive information on the therapeutics under
development for Vulvovaginal Candidiasis, complete with analysis by
stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved
in therapeutic development for Vulvovaginal Candidiasis and features
dormant and discontinued projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
Download
Sample copy of this Report @
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Vulvovaginal Candidiasis
-
The report reviews pipeline therapeutics for Vulvovaginal Candidiasis
by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved Vulvovaginal Candidiasis
therapeutics and enlists all their major and minor projects
-
The report assesses Vulvovaginal Candidiasis therapeutics based on
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news related to pipeline therapeutics for
Vulvovaginal Candidiasis
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand important and diverse types of therapeutics
under development for Vulvovaginal Candidiasis
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Vulvovaginal Candidiasis pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Table
of Content :
List
of Tables 4
List
of Figures 4
Global
Markets Direct Report Coverage 5
Vulvovaginal
Candidiasis Overview 6
Therapeutics
Development 7
Pipeline
Products for Vulvovaginal Candidiasis - Overview 7
Vulvovaginal
Candidiasis - Therapeutics under Development by Companies 8
Vulvovaginal
Candidiasis - Pipeline Products Glance 9
Clinical
Stage Products 9
Early
Stage Products 10
Unknown
Stage Products 11
Vulvovaginal
Candidiasis - Products under Development by Companies 12
Vulvovaginal
Candidiasis - Companies Involved in Therapeutics Development 13
Cidara
Therapeutics, Inc. 13
Grupo
Ferrer Internacional, S.A. 14
NovaDigm
Therapeutics, Inc. 15
Scynexis,
Inc. 16
TGV-Laboratories
17
Viamet
Pharmaceuticals, Inc. 18
Vulvovaginal
Candidiasis - Therapeutics Assessment 19
Assessment
by Monotherapy Products 19
Assessment
by Target 20
Assessment
by Mechanism of Action 22
Assessment
by Route of Administration 24
Assessment
by Molecule Type 26
Read
our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment